Expression of VEGF-C angiogenesis, lymphangiogenesis Cancer

Lymphangiogenic Gene Therapy, yellow nail syndrome, lymphatic vascular development, Intratumoral lymphatics, peritumoral lymphatics, stem cell research, Angiopoietins, VEGF, PIGF, FOXC1, FOXC2, Lymphatic Insufficiency. SOX18, lymphatic hyperplasia, Molecular lymphangiogenesis, PROX1, FLT3, Telan­giectasia, Lymphatic endothelial cells, adult vasculogenesis, LYVE1

Moderators: Birdwatcher, jenjay, Cassie, patoco, Senior Moderators

Expression of VEGF-C angiogenesis, lymphangiogenesis Cancer

Postby patoco » Wed Sep 20, 2006 1:31 pm

Expression of VEGF-C and angiogenesis, and lymphangiogenesis in papillary thyroid carcinoma

August 2006

Liang QC, Wei QY, Fan SQ. Department of Pathlology, Second Xiangya Hospital, Central South University, Changsha, China.

OBJECTIVE: To investigate the relationship between the expression of vascular
endothelial growth factor C (VEGF-C) and angiogenesis and
lymphangiogenesis in papillary thyroid carcinoma (PTC).

METHODS:

Seventy-two PTC cases were divided into 3 groups according to the level
of invasion: papillary microcarcinoma group (PMC group), intrathyroid
carcinoma group (IPC group), and extrathyroid carcinoma group (EPC
group). They were again divided into 2 groups according to lymph node
metastasis: lymph node metastasis group and lymph node no-metastasis
group. The expressions of VEGF-C, CD105 and vascular endothelial growth factor receptor-3 (VEGFR-3) were detected by SP method of
immunohistochemical staining. The expression of VEGF-C was analyzed
quantitatively by image analysis system, and the PI of VEGF-C
(VEGF-C-PI), the number of MVD (microvessel density), and LVD
(lymphaticvessel density) were obtained.

RESULTS:

The VEGF-C-PI of lymph node metastasis group (23.15 +/- 3.75) was
higher than that of lymph node non-metastasis group (14.54 +/- 2.93) (P
<0.01). MVD was 35.25 +/- 2.06 in the PMC group, 41.75 +/- 5.46 in the
IPC group, and 52.58 +/- 4.16 in the EPC group, which showed the
elevatory tendency with the increase of invasion (P < 00.5). LVD was
6.00 +/- 0.81 in the PMC group, 13.80 +/- 1.81 in the IPC group, and
19.17 +/- 2.96 in the EPC group, which again showed the elevatory
tendency with the increase of invasion (P <0.05). The LVD of lymph node
metastasis group (19.56 +/- 2.45) was significantly higher than that of
lymph node non-metastasis group (12.48 +/- 2.84) (P < 0.05). VEGF-C was positively correlated with MVD and LVD (r = 0.743, 0.90, P <0.01).

CONCLUSION:

The expressions of VEGF-C and LVD are related to lymph node metastasis
of PTC. MVD and LVD are related to the invasion of PTC. VEGF-C may play an important role in the angiogenesis and lymphangiogenesis.

PMID: 16859137 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/entrez/quer ... etrieve&...

---------

Related Abstract

Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D.

Miyata Y, Kanda S, Ohba K, Nomata K, Hayashida Y, Eguchi J, Hayashi T,
Kanetake H.
Department of Urology, Nagasaki University School of Medicine,
Sakamoto, Nagasaki, Japan. int.doc.m...@m3.dion.ne.jp

PURPOSE:

Lymph vessel density (LVD) and microvessel density (MVD)
correlate with the malignant potential of tumors and patient survival.
Vascular endothelial growth factors (VEGF)-A, VEGF-C, and VEGF-D could
modulate LVD and MVD. We investigated the clinical and prognostic
significance of LVD and MVD on lymphangiogenic and angiogenic function
of VEGF-A, VEGF-C, and VEGF-D in human bladder cancer.

EXPERIMENTAL DESIGN:

We reviewed tissue samples from patients with
nonmetastatic bladder cancer who had undergone transurethral resections
(n = 126). The densities of D2-40-positive vessels (LVD) and
CD34-positive vessels (MVD) were measured by a computer-aided image
analysis system. Expression of VEGF-A, VEGF-C, and VEGF-D was examined by immunohistochemistry; survival analyses and their independent roles were investigated using multivariate analysis models.

RESULTS:

LVD was associated with tumor grade but not with pT stage. LVD
was associated with metastasis-free survival (log rank P = 0.039), but
was not an independent prognostic factor. Although MVD affected
survival, the combination of high LVD and high MVD in tumors was an
independent predictor of metastasis-free survival. Although VEGF-C
expression was positively associated with both LVD and MVD, VEGF-D was
associated only with LVD. VEGF-A expression was associated with MVD in
univariate analysis, however, it was not an independent factor.

CONCLUSIONS:

Lymphangiogenesis and angiogenesis influence
metastasis-free survival, and are regulated by VEGF-C and/or VEGF-D.
Our results suggest that LVD and MVD are useful tools for the selection
of postoperative management and treatment strategies in patients with
bladder cancer.

PMID: 16467091 [PubMed - indexed for MEDLINE]

http://clincancerres.aacrjournals.org/c ... t/12/3/800

----------------

Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph
node metastasis of transitional cell carcinoma of the bladder.


Suzuki K, Morita T, Tokue A.
Department of Urology, Jichi Medical School, Tochigi, Japan.
s.k...@jichi.ac.jp

PURPOSE: It has been found that expression of vascular endothelial growth factor-C (VEGF-C) in several carcinomas is significantly associated with angiogenesis, lymphangiogenesis and regional lymph node metastasis. However, VEGF-C expression in bladder transitional cell carcinoma (TCC) has not yet been reported. To elucidate the role of VEGF-C in bladder TCC, we examined VEGF-C expression in bladder TCC and pelvic lymph node metastasis specimens obtained from patients who
underwent radical cystectomy.

METHODS: Eighty-seven patients who underwent radical cystectomy for clinically organ-confined TCC of the bladder were enrolled in the present study. No neoadjuvant treatments, except transurethral resection of the tumor, were given to these patients. The VEGF-C expressions of 87 bladder tumors and 20 pelvic lymph node metastasis specimens were examined immunohistochemically and the association between VEGF-C expression and clinicopathological factors, including angiogenesis as evaluated by microvessel density (MVD), was also examined.

RESULTS: Vascular endothelial growth factor-C expression was found in the cytoplasm of tumor cells, but not in the normal transitional epithelium. Vascular endothelial growth factor-C expression was significantly associated with the pathological T stage (P = 0.0289), pelvic lymph node metastasis (P < 0.0001), lymphatic involvement (P = 0.0008), venous involvement (P = 0.0002) and high MVD (P = 0.0043).

The multivariate analysis demonstrated that VEGF-C expression and high MVD in bladder TCC were independent risk factors influencing the pelvic
lymph node metastasis. Moreover, the patients with VEGF-C-positive
tumors had significantly poorer prognoses than those with the
VEGF-C-negative tumors (P = 0.0087) in the univariate analysis. The
multivariate analysis based on Cox proportional hazard model showed
that the independent prognostic factors were patient age (P = 0.0132)
and pelvic lymph node metastasis (P = 0.0333).

CONCLUSION: The present study suggests that VEGF-C expression is an important predictive factor of pelvic lymph node metastasis in bladder cancer patients.

http://www.blackwell-synergy.com/doi/ab ... 2005.010...

-----------

Lymphedema People

http://www.lymphedemapeople.com
User avatar
patoco
Site Admin
 
Posts: 2175
Joined: Thu Jun 08, 2006 9:07 pm

Return to Genetics, Research, Lymphangiogenesis, Angiogenesis

Who is online

Users browsing this forum: No registered users and 1 guest


cron